Zions Bancorporation N.A. Has $5.95 Million Stock Position in Stryker Co. (NYSE:SYK)

Zions Bancorporation N.A. lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 21.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 16,526 shares of the medical technology company’s stock after acquiring an additional 2,907 shares during the quarter. Zions Bancorporation N.A.’s holdings in Stryker were worth $5,950,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker during the 4th quarter worth $25,000. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. raised its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker in the fourth quarter worth approximately $30,000. Finally, BankPlus Trust Department bought a new stake in Stryker in the fourth quarter valued at approximately $33,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.9 %

Stryker stock opened at $374.43 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm’s fifty day moving average price is $384.55 and its two-hundred day moving average price is $374.24. The firm has a market capitalization of $142.87 billion, a price-to-earnings ratio of 48.25, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the business posted $3.46 EPS. On average, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.90%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research note on Tuesday, March 4th. Royal Bank of Canada upped their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Barclays lifted their price objective on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.